In the Claims

Amend the claims as follows:

1(Currently Amended) A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof: wherein,

R represents hydrogen, or C_{1-6} alkyl;

R_1 represents hydrogen or C_{1-6} alkyl, CF_3, C_{1-6} alkoxy, OH, COR^c, CO_2R_8, $CONHCH_2CO_2R$, $N(R)_2$, said alkyl and alkoxy optionally substituted with 1-3 groups selected from R^b;

X represents $-(CHR_7)_p-$;

Y represents $-CO(CH_2)_n-$, or -CH(OR)-;

Q represents N, CR^y, or O, wherein R_2 is absent when Q is O;

R^y represents H, or C_{1-6} alkyl;

R_w represents H, C_{1-6} alkyl, $-C(O)C_{1-6}$ alkyl, $-C(O)OC_{1-6}$ alkyl, $-SO_2N(R)_2$, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{6-10}$ aryl, NO_2, CN or $-C(O)N(R)_2$;

R_2 represents hydrogen, C_{1-10} alkyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-N(R)_2$, -COOR, or $-(CH_2)_nC_{6-10}$ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R_3 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-(CH_2)_nCOOR$, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nNHR_8$, $-(CH_2)_nN(R)_2$, $-(CH_2)_nN(R_8)_2$, $-(CH_2)_nNHCOOR$, $-(CH_2)_nN(R_8)CO_2R$, $-(CH_2)_nN(R_8)COR$, $-(CH_2)_nNHCOR$, $-(CH_2)_nCONH(R_8)$, aryl, $-(CH_2)_nC_{1-6}$-OR, CF_3, $-(CH_2)_nSO_2R$, $-(CH_2)_nSO_2N(R)_2$, $-(CH_2)_nCON(R)_2$, $-(CH_2)_nCONHC(R)_3$, $-(CH_2)_nCONHC(R)_2CO_2R$, $-(CH_2)_nCOR_8$, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of R^a;

or, when Q is N, R_2 and R_3 taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_4 and R_5 independently represent hydrogen, C_{1-6} alkoxy, OH, C_{1-6} alkyl, COOR, SO_3H, C_{1-6} alkylcarbonyl, $S(O)qR^y$, $-O(CH_2)_nN(R)_2$, $-O(CH_2)_nCO_2R$, $-OPO(OH)_2$, CF_3, $-N(R)_2$, nitro, cyano, C_{1-6} alkylamino, or halogen;

R_6 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{6-10}$ aryl, $-NH(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-NH(CH_2)_nC_{5-10}$ heteroaryl, $(C_{6-10}$ aryl)O-, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, -COOR, $-C(O)CO_2R$, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a;

R_7 represents hydrogen, C_{1-6} alkyl, $-(CH_2)_nCOOR$ or $-(CH_2)_nN(R)_2$,

R_8 represents -$(CH_2)_nC_{3-8}$ cycloalkyl, -$(CH_2)_n$ 3-10 heterocyclyl, C_{1-6} alkoxy or -$(CH_2)_nC_{5-10}$ heteroaryl, -$(CH_2)_nC_{6-10}$ aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF_3, $N(R)_2$, NO_2, CN, -$(CH_2)_nCOR_8$, -$(CH_2)_nCONHR_8$, -$(CH_2)_nCON(R_8)_2$, -$O(CH_2)_nCOOR$, -$NH(CH_2)_nOR$, -COOR, -OCF_3, -NHCOR, -SO_2R, -SO_2NR_2, -SR, (C_1-C_6 alkyl)O-, -$(CH_2)_nO(CH_2)_mOR$, -$(CH_2)_nC_{1-6}$ alkoxy, (aryl)O-, -OH, (C_1-C_6 alkyl)$S(O)_m$-, H_2N-C(NH)-, (C_1-C_6 alkyl)C(O)-, (C_1-C_6 alkyl)OC(O)NH-, -(C_1-C_6 alkyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)-C_{3-10} heterocyclyl-R_w, -$(CH_2)_n$-Z^1-$C(=Z^2)N(R)_2$, -(C_{2-6} alkenyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)-C_{3-10} heterocyclyl-R_w, -(C_{2-6} alkenyl)-Z^1-$C(=Z^2)N(R)_2$, -$(CH_2)_nSO_2R$, -$(CH_2)_nSO_3H$, -$(CH_2)_nPO(OR)_2$, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C_{2-6} alkenyl, and C_1-C_{10} alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C_1-C_6 alkyl, and COOR;

Z^1 and Z^2 independently represents NR_w, O, CH_2, or S;

R^b represents C_{1-6} alkyl, -COOR, -SO_3R, -$OPO(OH)_2$, -$(CH_2)_nC_{6-10}$ aryl, or -$(CH_2)_nC_{5-10}$ heteroaryl;

R^c represents hydrogen, C_{1-6} alkyl, or -$(CH_2)_nC_{6-10}$ aryl;

m is 0-3;
n is 0-3;
q is 0-2; and
p is 0-1,
provided that the compound of formula I is not 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-[5-(1-methylethyl)-2-thizaolyl; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-pyridinyl ester; or 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-3-pyridinyl.

2(Original). A compound of the structural formula I wherein X is CHR_7.

3 (Original). A compound according to claim 1 wherein Y is -$CO(CH_2)_n$.

4(Original). A compound according to claim 1 wherein Y is CH(OR).

5(Original). A compound according to claim 1 wherein Q is N.

6(Original). A compound according to claim 1 wherein Q is CH.

7(Original). A compound according to claim 2 wherein R_6 is $(CH_2)_nC_{6-10}$ aryl, $(CH_2)_nC_{5-10}$ heteroaryl, $(CH_2)_nC_{3-10}$ heterocyclyl, or $(CH_2)_nC_{3-8}$ cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

8(Original). A compound according to claim 6 wherein R_7 is hydrogen or C_{1-6} alkyl.

9(Original). A compound according to claim 6 wherein Q is N and n is 0.

10(Original). A compound according to claim 1 wherein Y is -$CO(CH_2)_n$, Q is N, n is 0, R_2 is C_{1-10} alkyl or C_{1-6} alkylOH and R_3 is $(CH_2)_nC_{3-10}$ heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

Cancel claims 11-24.

Add new claims 25 through 29:

25 (New). A composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound according to claim 1.

26 (New). A compound according to claim 11 which is:

Table 1



Wherein R represents:







$-N(OCH_3)CH_3$, $-NH(CH_2)_3NH_2$, $-NH(CH_2)_3NHCO_2X$

$-NH(CH_2)_2NHCO_2X$, or $-NHC_{1\text{-}6}$alkyl;

n is 0 to 3; X, Y and Z, independently represent hydrogen or $C_{1\text{-}6}$ alkyl; and Rc represents hydrogen, halogen, $C_{1\text{-}6}$ alkyl, CF3, OCF3, N(CH3)3, $COC_{1\text{-}6}$ alkyl, or methoxy;

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

27 (New). The compound according to claim 11 which

Table 2



wherein R represents:



n is 0 to 3; s is 1-5; X represents hydrogen or C_{1-6} alkyl; R^b and R^a independently represent hydrogen, methoxy, CO_2X, NHAc, or C_{1-6} alkyl; R^c represents hydrogen, halogen, C_{1-6} alkyl, CF_3, OCF_3, $N(CH_3)_2$, COC_{1-6} alkyl, or methoxy

is:

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

28 (New). The compound according to claim 11 which is:

Table 3



wherein R represents:









,



,



,



,



,



;

n is 0 to 3; s is 1-5; X represents hydrogen or C_{1-6} alkyl; and R^c represents hydrogen, halogen, C_{1-6} alkyl, CF_3, OCF_3, $N(CH_3)_2$, COC_{1-6} alkyl, or methoxy or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

29 (New). The compound according to claim 11 which is:

Table 4



,



or



wherein:
R^b and R^a independently represent hydrogen, methoxy, CO_2X, NHAc, or C_{1-6} alkyl;

R^d represents C1-6 alkyl, pyridinyl, -O-phenyl, phenyl, thienyl, said pyridinyl and phenyl optionally substituted with 1-3 halogen, CF_3, OCF_3, $N(CH_3)_2$, methoxy or C1-6 alkyl; and

R^e represents methoxy, $O(CH_2)_2N(CH_3)_2$, or OH;

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.